We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Miscellaneous 0.08%
3 Technology 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WAY
76
Waystar Holding Corp
WAY
$4.81B
$4.93M 0.1%
129,913
-20,697
-14% -$767K
GKOS icon
77
Glaukos
GKOS
$10.5B
$4.56M 0.09%
55,926
– –
SIBN icon
78
SI-BONE Inc
SIBN
$829M
$4.4M 0.09%
298,857
-241,255
-45% -$3.94M
INSP icon
79
Inspire Medical Systems
INSP
$1.82B
$4.35M 0.09%
58,648
-17,012
-22% -$1.72M
LH icon
80
Labcorp
LH
$26.5B
$4.32M 0.09%
15,065
-21,627
-59% -$5.79M
ICLR icon
81
Icon
ICLR
$12.7B
$4.24M 0.09%
+24,247
New +$4.06M
AMGN icon
82
Amgen
AMGN
$236B
$4.23M 0.09%
14,988
-9,120
-38% -$2.64M
CVS icon
83
CVS Health
CVS
$124B
$3.86M 0.08%
51,199
+21,103
+70% +$1.45M
TXG icon
84
10x Genomics
TXG
$8.16B
$3.67M 0.08%
313,836
-12,915
-4% -$168K
BNTX icon
85
BioNTech
BNTX
$26.1B
$3.35M 0.07%
33,955
-1,084
-3% -$116K
KMTS
86
Kestra Medical Technologies
KMTS
$1.5B
$3.06M 0.06%
128,711
-5,050
-4% -$90.3K
INSM icon
87
Insmed
INSM
$27.6B
$2.92M 0.06%
20,251
-61,146
-75% -$7.49M
MRK icon
88
Merck
MRK
$371B
$2.92M 0.06%
34,739
+6,500
+23% +$535K
NEO icon
89
NeoGenomics
NEO
$2.23B
$2.86M 0.06%
370,198
-542,884
-59% -$3.8M
LEGN icon
90
Legend Biotech
LEGN
$4.19B
$2.77M 0.06%
84,976
-462
-0.5% -$17.1K
AZN icon
91
AstraZeneca
AZN
$252B
$2.73M 0.06%
17,822
-1,378
-7% -$209K
CAH icon
92
Cardinal Health
CAH
$57.5B
$2.55M 0.05%
16,268
-3,744
-19% -$578K
ADPT icon
93
Adaptive Biotechnologies
ADPT
$3.87B
$2.52M 0.05%
+168,476
New +$2.05M
ILMN icon
94
Illumina
ILMN
$33B
$2.26M 0.05%
23,797
-3,827
-14% -$380K
BMY icon
95
Bristol-Myers Squibb
BMY
$136B
$2.15M 0.04%
47,613
+10,436
+28% +$487K
SPY icon
96
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$2.07M 0.04%
3,100
– –
VKTX icon
97
Viking Therapeutics
VKTX
$4.07B
$2M 0.04%
+76,082
New +$2.27M
BAX icon
98
Baxter International
BAX
$13.4B
$1.55M 0.03%
68,084
-84,207
-55% -$2.14M
COR icon
99
Cencora
COR
$63.2B
$1.52M 0.03%
4,850
-3,120
-39% -$918K
GDX icon
100
VanEck Gold Miners ETF
GDX
$30.7B
$1.41M 0.03%
18,500
-7,700
-29% -$464K
2 3
4
5 6

Similar funds

SP
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
NHC
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.